Related Experiment Video

Updated: Jul 9, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.6K

Binding Thermodynamics of Fourth-Generation EGFR Inhibitors Revealed by Absolute Binding Free Energy Calculations

Huaxin Zhou1,2, Haohao Fu1,2,3, Xueguang Shao1,2,3

  • 1Research Center for Analytical Sciences, Tianjin Key Laboratory of Biosensing and Molecular Recognition, State Key Laboratory of Medicinal Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China.

Journal of Chemical Information and Modeling
|December 6, 2023
PubMed

Insights

Fourth-generation EGFR TKIs like BLU-945 show strong binding to resistant EGFR mutations in non-small-cell lung cancer, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Epidermal growth factor receptor (EGFR) mutations drive non-small-cell lung cancer (NSCLC).
  • EGFR tyrosine kinase inhibitors (TKIs) are effective but face resistance due to mutations.
  • Understanding resistance mechanisms is crucial for developing next-generation therapies.

Purpose of the Study:

  • To investigate the binding affinities of the fourth-generation TKI BLU-945 and its analogues to wild-type (EGFRWT), double-mutant (EGFRDM), and triple-mutant (EGFRTM) EGFR.
  • To compare BLU-945's binding with erlotinib (first-generation TKI) and another fourth-generation TKI, CH7233163.
  • To elucidate the molecular interactions and key residues involved in TKI binding to resistant EGFR forms.

Main Methods:

  • Absolute binding free energy calculations were employed.
  • Binding affinities of BLU-945, analogues, CH7233163, and erlotinib were computed.
  • Molecular interactions and key binding residues were identified.

Main Results:

  • BLU-945 and CH7233163 demonstrated superior binding affinities to EGFRDM and EGFRTM compared to erlotinib.
  • Key residues K745 and T854 were identified as critical for fourth-generation TKI binding.
  • Electrostatic forces were the primary drivers for fourth-generation TKI binding to EGFR mutants.
  • Piperidinol and sulfone groups in BLU-945 significantly enhanced binding to EGFR mutants.

Conclusions:

  • Fourth-generation EGFR TKIs exhibit potent binding to common resistance mutations in NSCLC.
  • Structural insights from this study can guide the optimization of novel EGFR-targeted therapies.
  • BLU-945 and similar compounds represent promising candidates for overcoming TKI resistance in NSCLC.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K
Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens07:39

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

6.3K

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.9K
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
47
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
210